Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi最新文献_第2页

Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis 新冠肺炎危机时期癌症患者静脉化疗依从性分析

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2020-09-30 DOI: 10.4999/UHOD.204528

I. Beypınar, M. Urun

{"title":"Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis","authors":"I. Beypınar, M. Urun","doi":"10.4999/UHOD.204528","DOIUrl":"https://doi.org/10.4999/UHOD.204528","url":null,"abstract":"SARS-CoV-2 is a single-stranded RNA spherical virus spikes formed by glycoproteins The leading cause of death was linked to acute respiratory distress syndrome, myocardial injury, or renal failure After the first case reported on the 11th of March in Turkey Ministry of Health and Interior declared some regulations on the public, such as travel restrictions, traffic restrictions, social distancing homes, and centralized quarantine Although chemotherapy adherence is a highly studied area for both oral and intravenous agents in cancer patients, no available data exist in a pandemic world with many social restrictions The records of patients who have active cancer treatment in the department of medical oncology retrospectively analyzed The age, gender, diagnosis, chemotherapy type, rendezvous, and coming dates recorded Four chemotherapy delays (3 7%) were observed out of 52 patients before the 11th of March 2020, while 43 chemotherapy delays (39,8%9) occurred out of 107 patients after the first COVID-19 case and the restrictions in Turkey Twenty patients had treatment delay without reason and did not show up for treatment on the day of chemotherapy The treatment delays without reasons are significantly different in the pre and post COVID-19 pandemic era The hematologic toxicity rates were similar when compared pre and post COVID-19 period The non-specific regulations and declarations confuse the patients and prevent them from reaching the treatment which is needed In the case of pandemic regulations, oncologic patients may have special considerations for government decisions © 2020, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi All rights reserved","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82728047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

The Assessment of the Relationship Between ABO Blood Groups and Covid-19 Infection ABO血型与Covid-19感染关系的评价

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2020-09-30 DOI: 10.4999/UHOD.204348

S. Aktimur, A. Şen, B. Yazıcıoğlu, A. Gunes, S. Genç

{"title":"The Assessment of the Relationship Between ABO Blood Groups and Covid-19 Infection","authors":"S. Aktimur, A. Şen, B. Yazıcıoğlu, A. Gunes, S. Genç","doi":"10.4999/UHOD.204348","DOIUrl":"https://doi.org/10.4999/UHOD.204348","url":null,"abstract":"The new coronavirus disease-2019 (COVID-19) is rapidly spreading around the world and has been declared an outbreak by WHO However, the effect of blood groups on COVID-19 infection and the severity of the disease is unclear The aim of this study is to determine the relationship between ABO blood group and susceptibility to COVID-19 infection and whether the blood group will be a biomarker for COVID-19 infection Patients diagnosed with SARS-CoV-2 between March and May 2020 were included in this study In order to compare the blood groups of the patients with the healthy group, patients who had previously performed ABO blood group analysis in the blood bank between February and May 2020 were included as the control group Demographic data, clinical data, underlying comorbidities, laboratory findings and clinical results (hospitalization, need for intensive care, mortality) were obtained from the electronic medical records A total of 179 patients with confirmed COVID-19 and 5200 healthy control patients were included in the study Patients with COVID-19 showed a distribution of 62 01% in group A,9 50% in group B, 8 94% in group AB and 19 55% in group O In group A, length of stay in Intensive Care Unit was longer (10 42±11 61 days;p= 0 013) Compared to the blood groups of the healthy control group, COVID-19 patients had higher A blood group than the healthy group (62& vs 46 6%;p 0 001) and lesser of the O blood group (19 6% vs 34 7%;p 0 001) Blood group A can be used as a predictive biomarker for COVID-19 disease In addition, we concluded that the group A had a higher risk for COVID-19 disease and severity © 2020, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi All rights reserved","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73741875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Association Between the Rh Blood Group and the Covid-19 Susceptibility Rh血型与Covid-19易感性的关系

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2020-06-30 DOI: 10.4999/uhod.204247

Eşref Araç, Ihsan Solmaz, H. Akkoç, S. Dönmezdil, Zülküf Karahan, S. Kaya, Yılmaz Mertsoy, M. S. Yıldırım, N. Ekin, S. Araç, C. Demir

{"title":"Association Between the Rh Blood Group and the Covid-19 Susceptibility","authors":"Eşref Araç, Ihsan Solmaz, H. Akkoç, S. Dönmezdil, Zülküf Karahan, S. Kaya, Yılmaz Mertsoy, M. S. Yıldırım, N. Ekin, S. Araç, C. Demir","doi":"10.4999/uhod.204247","DOIUrl":"https://doi.org/10.4999/uhod.204247","url":null,"abstract":"We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems This study was a retrospective study that investigate the patients admitted to our hospital between March 16 -May 20 due to Covid-19 pandemic and conducted with data revealed from the hospital Information Management System A total of 392 patients were included in this study, including 227 PCR test positive patients with blood group information in the system and 165 possible patients with CT findings in favor of Covid-19 Data from a blood group study conducted with 127091 people in our province in 2019 were used as a control group In our study, a significant increase was observed in the blood group A in patients diagnosed with Covid-19, and a decrease was found in the blood groups B, AB and especially O However, statistical analysis showed no significant difference between Covid-19 patients and healthy individuals in terms of ABO blood group system When analyzed in terms of Rh blood group system, it was found that Rh positivity was statistically significantly higher in patients with Covid-19 (p= 0 000) Our study suggests that the Rh (-) blood group is protective and the Rh (+) blood group is predisposed to Covid 19 significantly We think that it is valuable because it is the first study to reveal the relationship between Covid-19 and blood type in our country and the only one to reveal the relationship between Covid-19 and Rh (+) in the world literature","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74096880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

A macrophage at work 巨噬细胞在起作用

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2017-01-01 DOI: 10.4999/UHOD.171981

B. Kahwash, S. Kahwash, G. Tan

引用次数: 0

Küçük hücreli dışı akciğer kanserli hastaların tedavisinde hibrid volümetrik ark radyoterapi, yoğunluk ayarlı radyoterapi ve volumetrik yoğunluk ayarlı ark radyoterapisinin avantajlarını birleştirerek, hızlı, konformal ve homojen bir tedaviyi düşük doz banyosundan sakınarak yapabilmektedir: Dozimetr

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2017-01-01 DOI: 10.4999/UHOD.172064

Y. Sağlam, Yasemin Bolukbasi, Vildan Alpan, Erkan Topkan, Steve M. Kirsner, Matthew Ballo, Joe Y. Chang, A. Bingolbali, Uğur Selek

引用次数: 0

Tıp bilimlerinde yayinlanan makalelerin istatistiksel hatalar bakimindan incelenmesi

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2015-09-19 DOI: 10.4999/UHOD.15942

Ilker Ercan, P. Karadeniz, Sengul Cangur, Güven Özkaya, Hakan Demirtaş

引用次数: 3

Macrolide Treatment for Primary Immune Thrombocytopenia 大环内酯治疗原发性免疫性血小板减少症

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2014-03-01 DOI: 10.4999/UHOD.13066

M. Ohe, S. Hashino

引用次数: 1

foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2012-12-01 DOI: 10.4999/UHOD.11035

Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier

{"title":"foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi","authors":"Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier","doi":"10.4999/UHOD.11035","DOIUrl":"https://doi.org/10.4999/UHOD.11035","url":null,"abstract":"Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83738446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

böbrek kanserinin gelişliminde arsenik ve karsinojenik mutasyonlari{dotless}n rolü

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2012-01-01 DOI: 10.4999/UHOD.11079

Bekir Tanriover

引用次数: 2

Catastrophic antiphospholipid syndrome in a patient with immune thrombocytopenic purpura 免疫性血小板减少性紫癜患者的灾难性抗磷脂综合征

IF 0.6 4区医学

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi Pub Date : 2011-09-01 DOI: 10.4999/UHOD.10095

S. John, K. McCrae

引用次数: 0